<div id="readability-page-1"><div><ul> <li>If you are wondering whether Hinge Health is attractively priced or already baking in a lot of optimism, this article is designed to help you frame that question clearly.</li> <li>The stock last closed at US$45.00, with a 16.1% gain over the past 30 days, but a 2.5% decline over the last week and a 1.2% decline year to date. This hints at shifting views on both its potential and its risks.</li> <li>Recent news coverage has focused on Hinge Health's position as a listed musculoskeletal care company, along with market interest in how digital health names are being valued over time. This context helps explain why the share price has seen mixed short term moves as investors weigh its long term role in the healthcare sector.</li> <li>On our valuation checks, Hinge Health scores a 3 out of 6. In the sections that follow we will compare different valuation approaches and then circle back to a broader framework that can help you interpret those numbers more effectively.</li> </ul> Hinge Health delivered 0.0% returns over the last year. See how this stacks up to the rest of the Healthcare industry. <h3>Approach 1: Hinge Health Discounted Cash Flow (DCF) Analysis</h3> A Discounted Cash Flow, or DCF, model estimates what a company might be worth today by projecting its future cash flows and then discounting those back to a single present value number. For Hinge Health, the model used is a 2 Stage Free Cash Flow to Equity approach, based on cash flow projections in US$. The latest twelve month free cash flow is reported at about $164.8 million. Analysts and internal estimates then project annual free cash flows out to 2035, with the 2030 estimate sitting at $446.0 million, of which $318.3 million is the discounted value in today's terms. Adding up all these discounted cash flows gives an estimated intrinsic value of about $155.02 per share. Compared with the recent share price of US$45.00, the model implies the stock trades at about a 71.0% discount to this DCF estimate. This indicates a wide valuation gap based on these assumptions. Result: UNDERVALUED Our Discounted Cash Flow (DCF) analysis suggests Hinge Health is undervalued by 71.0%. Track this in your watchlist or portfolio, or discover 48 more high quality undervalued stocks. Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Hinge Health. <h3>Approach 2: Hinge Health Price vs Sales</h3> For companies where earnings are not the main focus yet, the P/S ratio can be a useful way to think about valuation, because it compares what investors are paying to the revenue the business is already generating. In general, higher growth expectations and lower perceived risk tend to justify a higher “normal” or “fair” multiple, while slower growth or higher risk usually point to a lower one. That context matters when you look at Hinge Health’s current P/S of 6.03x. The Healthcare industry average P/S sits at 1.23x and Hinge Health’s peer group averages 4.23x, so the stock is valued above both of those simple benchmarks. Simply Wall St’s Fair Ratio for Hinge Health is 5.71x, which is its proprietary estimate of what a reasonable P/S might be after considering factors such as earnings growth, profit margins, industry, market cap and key risks. Because the Fair Ratio incorporates those company specific drivers, it can be more useful than a straight comparison with broad industry or peer averages that do not adjust for growth or risk profile. Here, the actual P/S of 6.03x sits modestly above the Fair Ratio of 5.71x, which indicates the shares trade on a richer multiple. Result: OVERVALUED P/S ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies. <h3>Upgrade Your Decision Making: Choose your Hinge Health Narrative</h3> Earlier we mentioned that there is an even better way to understand valuation, so on Simply Wall St’s Community page you can use Narratives to link your view of Hinge Health’s story to a set of revenue, earnings and margin forecasts, see how that translates into a Fair Value, compare that to the current price to help you decide whether it looks more like a buy or a sell for you, and watch that view update automatically as new earnings or news arrive, whether you lean closer to a bullish fair value of US$72.00 or a more cautious fair value of about US$43.40. For Hinge Health however we'll make it really easy for you with previews of two leading Hinge Health Narratives: 🐂 Hinge Health Bull Case Fair value in this bullish narrative: US$72.00 per share Implied discount to that fair value at US$45.00: about 37.5% undervalued Revenue growth assumption in this view: 24.3% a year <ul> <li>Backers of this view see Hinge Health scaling its musculoskeletal platform across roughly 24.6 million contracted lives, using that reach to support revenue growth and net dollar retention above 110%.</li> <li>They expect AI powered tools and the Robin assistant to help keep gross margins in the low to mid 80% range and support an operating margin around 20% with free cash flow margin around 31%.</li> <li>This group is comfortable with a higher future P/E of about 47.9x on projected 2029 earnings of US$177.7 million. This is above the current US Healthcare industry P/E of 22.4x and uses a discount rate of roughly 7.0%.</li> </ul> 🐻 Hinge Health Bear Case Fair value in this bearish narrative: about US$43.40 per share Implied premium to that fair value at US$45.00: about 3.7% overvalued Revenue growth assumption in this view: 16.9% a year <ul> <li>This camp focuses on the reliance on employer and health plan budgets, pointing out that converting roughly 25 million contracted lives into higher billings may be slower if benefit designs and engagement do not keep up.</li> <li>They see a risk that efficiency gains from AI and Robin are harder to repeat from here, while HingeSelect and new reimbursement channels may require several years of investment before contributing meaningfully.</li> <li>On their numbers, Hinge Health would reach 2029 earnings of about US$125.4 million and trade on a P/E of roughly 41.3x, again above the current US Healthcare industry P/E, with the narrative fair value close to today’s share price.</li> </ul> If you want to go beyond these snapshots and read how each thesis is built line by line, the full community views are a useful next step, starting with Curious how numbers become stories that shape markets? Explore Community Narratives. Do you think there's more to the story for Hinge Health? Head over to our Community to see what others are saying! This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</div></div>

HNGE

Hinge Health's stock recently closed at $45.00, reflecting a 16.1% gain over 30 days but a decline of 2.5% in the last week. A Discounted Cash Flow analysis suggests the stock is undervalued by 71%, with an intrinsic value of $155.02 per share. However, its Price-to-Sales ratio of 6.03x is above industry averages, indicating it may be overvalued. Analysts provide varying fair value estimates, ranging from $43.40 to $72.00, prompting investors to reassess its market position and potential risks.

Simplywall

SPDR S&P Health Equip

Is It Time To Reassess Hinge Health (HNGE) After Its Recent Share Price Rebound?